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bstract
In vivo imaging using positron emission tomography (PET) is important in the development of new radiopharmaceuticals in rodent
nimal models for use as biochemical probes, diagnostic agents, or in drug development. We have shown mathematically that, if small
nimal imaging studies in rodents are to have the same “quality” as human PET studies, the same number of coincidence events must be
etected from a typical rodent imaging “voxel” as from the human imaging voxel. To achieve this using the same specifi activity
reparation, we show that roughly the same total amount of radiopharmaceutical must be given to a rodent as to a human subject. At high
pecifi activities, the mass associated with human doses, when administered to a rodent, may not decrease the uptake of radioactivity at
on saturable sites or sites where an enzyme has a high capacity for a substrate. However, in the case of binding sites of low density such
s receptors, the increased mass injected could saturate the receptor and lead to physiologic effects and non-linear kinetics. Because of the
mportance of the mass injected for small animal PET imaging, we experimentally compared high and low mass preparations using ex vivo
iodistribution and phosphorimaging of three compounds: 2-fluoro-2-deoxyglucos (FDG), 6-fluoro-L-metatyrosin (FMT) and one
eceptor-directed compound, the serotonin 5HT1A receptor ligand, trans-4-fluoro-N-{2-[4-(2-methoxylphenyl piperazino]ethyl}-N-(2-
yridyl) cyclohexane- carboxamide (FCWAY). Changes in the mass injected per rat did not affect the distribution of FDG, FMT, and
CWAY in the range of 0.6–1.9 nmol per rat. Changes in the target to nontarget ratio were observed for injected masses of FCWAY in
he range of5–50 nmol per rat. If the specifi activity of such compounds and/or the sensitivity of small animal scanners are not increased
elative to human studies, small animal PET imaging will not correctly portray the “true” tracer distribution. These difficultie will only be
xacerbated in animals smaller than the rat, e.g., mice.
eywords Animal imaging; PET; FDG; FMT; FCWAYt
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r. Introduction
The driving force for the development of small animal
ET scanners is threefold: the availability of various disease
odels presently available in small animals, the advantage
f paired statistics when using serial imaging compared to
erial autopsy, and the need to replace, reduce, and refin
nimal use [1]. Most of the animal models of neurological
isease [2], cardiovascular disease [3], and cancer [4] are in
odents. The choice of the animal species is determined by
he general knowledge of the neuroanatomy and neuro-
hemistry, the ability to investigate behavioral responses
nd the cost to purchase and house the species. Rats and
ice meet many of these conditions.
PET radiopharmaceuticals fall into three categories: (1)chose that trace nonsaturable systems (e.g. [18F] fluorid in
one), (2) intermediate saturable systems (e.g., 2-[18F]
luoro-2-deoxyglucos (FDG) to measure changes in glu-
ose transporter (GLUT) and hexokinase activity, and
-[18F]fluoro-metatyrosin (FMT) to measure dopamine
etabolism), and (3) easily saturable, low-density systems
e.g., [18F] labeled FCWAY, a 5-HT1A antagonist to mea-
ure changes in 5-HT1A receptor density). Another example
f the latter case is [18F] labeled dVIP, a radioligand to
easure VIP receptor density in tumors [5].
These three classes of radiopharmaceuticals present in-
reasing imaging challenges as the density of the target site
ecreases. If we assume that studies are performed in hu-
ans with minimal saturation of the target sites at the
ttainable specifi activity, we can mathematically deduce
he conditions necessary to obtain comparable images in
odents and then experimentally test the effect of these
onclusions in rats using the three classes of radiopharma-
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[euticals. We show with a simple mathematical argument
hat comparable images are obtained only when the amount
f radioactivity administered to the rat is roughly the same
s to the human. Thus, we compared biodistribution data in
ats obtained with milliCurie, or human, level doses of
njected tracer (by autoradiography) to microCurie amounts
f injected tracer (by dissection and well counting) to iden-
ify potential violations of the tracer principal within these
lasses. Studies using PiPET were also performed to show
hat comparable images can be obtained in the rat brain [6].
. Materials and methods
.1. Radiopharmaceuticals
The [18F]f uoride was taken directly from the 18O target
fter proton irradiation and dissolved in phosphate buffer.
he 2-[18F]FDG was prepared by the Hamacher method [7].
he 6-[18F]FMT was prepared following the publication of
amavari et al. [8]. To block aromatic amino acid decar-
oxylase (AAAD), carbidopa (5 mg/kg) was administered
.c. 30 min before 6-[18F]FMT. The trans-[18F]FCWAY
as prepared by the method of Lang et al. [9].
.2. Rat biodistribution studies
Adult male Sprague-Dawley rats (200–250 g) were in-
ected intravenously with either 2-[18F]FDG or trans-
18F]FCWAY and intra-peritoneally with 6-[18F]FMT (pre-
njected with carbidopa as described above) (Table 1). The
ats were sacrif ced at times between 30 and 45 min post-
njection of the F-18 labeled radiopharmaceutical and the
rain was immediately placed in 0.3 M sucrose on ice. The
rain was dissected on ice; the blood and various brain
issues were collected and weighed. The radioactive content
f the blood and various tissues was assayed by gamma
ounting. Reported ratios were obtained using the DUR
alues (differential uptake ratio is %injected dose/g of target
able 1
roperties of the compounds used for dissection studies.
adiopharmaceuticals mCi
injected
Specif c
activity
Ci/mmol*
nmol
injected
-[18F]FDG 4 1,000 4
-[14C]FDG 0.050 0.3 167
-[18F]FDG 0.050 1000 0.02
-[14C]FDG 0.050 0.3 167
-[18F]FMT with carbidopa 0.050 0.49 102
18F]FCWAY 0.050 869 0.089
* TOI  time of injection.issue body weight (g)/100). (.3. Rat ex vivo autoradiography and data analysis
Adult male Sprague-Dawley rats (200–250g) were in-
ected intravenously with the amount of radiopharmaceuti-
al listed in Table 2 and sacrif ced after 30 min. The carbi-
opa was pre-injected as described previously. The brains
ere removed, immediately quick frozen in dry ice, and cut
nto 20 m slices using a BIHI cytomicrotome (Bright
nstrument Co. and Hacker Instrument Inc, B2589). The
lices were placed on slides, air dried, and placed on a
hosphorimaging plate with a pixel size of 25 m2 (Fuji
AS-SR2025). After exposure the plates were scanned us-
ng a Fuji Bio-imaging Analysis System 5000. These plates
ave a high cross section for beta particles and relatively
ow cross section for gamma rays.
The quantitative data expressed as differential uptake
atio/m2 of target tissue (DUR/m2) were determined by
orrelating cpm to PSL (photo-stimulated luminescence
nits). For each study adjacent brain slices at 6 different
egions throughout the brain were used to determine the
inear relationship of PSL to cpm (cpm slopePSL). One
lice was exposed to the phosphorimaging plate overnight
nd the adjacent slice was counted on a 1480 Wallac Wizard
amma counter. Using the PSL units associated with the
hosphorimaging slice and the cpm from the adjacent slice,
he slope of the line was determined for each study (the
lope varied from 0.169–0.192 between studies). Using this
elationship, regions of interest could be converted from
SL/m2 to cpm/m2, which was used to calculate DUR/m2
y the following equation:
DUR/m2
(cpm/m2) (body weight (g))
cpm injected 100
The area of interest on the phosphor plate was not mul-
iplied by the slice thickness of 20 m to give a measure of
adioactivity per volume because of the additional assump-
ions concerning the eff ciency of collecting positron decay
t different depths.
.4. Imaging using PiPET
As an adjunct to the in vitro measurements, we per-
ormed imaging studies in a group of rats using the PiPET
able 2
roperties of the compounds used for autoradiography.
adiopharmaceuticals mCi
injected
Specif c
activity
Ci/mmol*
nmol
injected
-[18F]FDG 4 1,000 4
-[18F]FMT with carbidopa 3 0.60 5,000
18F]FCWAY 1 1266 1.0
* TOI  time of injection.6) small animal PET imaging system, PiPET is comprised
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[f two opposed bismuth germanate (BGO) detector modules
0-cm apart and operated in time coincidence. Each detector
onsists of a 2622 array of 2 mm2 mm10 mm long
GO crystals coupled with optical grease to the face of a
amamatsu R3941 position-sensitive photomultiplier tube
PSPMT). Each crystal is polished on f ve sides and f nely
round on its entrance end. All crystals are double-wrapped
n their long sides with PTFE tape including the entrance
nd. The f eld-of-view of PiPET is 55 mm (transverse)45
m (axial).
Tomographic imaging is performed by attaching the ob-
ect to be imaged to a vertical rotation stage placed midway
etween the detectors. During data acquisition, the object is
otated continuously around this vertical axis to acquire all
ossible lines-of-response. Tomographic images are then
econstructed from lines that fall within a user-selected
ange of angles relative to the detector normals. The abso-
ute central point source sensitivity of PiPET is 130 cps/Ci
ith an isotropic reconstructed spatial resolution of 2.1 mm
FWHM) using f ltered back-projection and ramp f lter.
mages shown in this report were reconstructed with the 3D
SEM resolution recovery algorithm (20 iterations) rather
han FBP. Spatial resolution in these images is estimated at
.5 mm. This scanner and its use have been described
reviously [6].
.5. Rat PiPETstudies and data analysis
Adult male Sprague-Dawley rats (200–250g) were in-
ected with the amount of the 18F labeled radiopharmaceu-
able 3
roperties of radiopharmaceuticals used for PiPET imaging.
adiopharmaceuticals Sacrif ce
time
(min)
mCi
injected
Specif c
activity
Ci/mmol*
nmol
injected
18F]f uoride 120 1 1,000 1
-[18F]FDG 45 4 1,000 4
-[18F]FMT with carbidopa 45 4.4 0.70 6,298
18F]FCWAY
Brain only 30 2.0 3,283 0.6
* TOI  time of injection.
able 4
atios of rat regional brain uptake to cerebellum (CB) for [18F]FDG and
in.
Dose (Ci) Cortex/CB Caudate/
18F]FDG 100 1.37  0.05* 1.46  0
14C]FDG 10 1.43  0.02* 1.54  0
18F]FDG 4000 1.62  0.07† 1.69  0
14C]FDG 50 1.61  0.07† 1.65  0
Values in bold are signif cantly different from one (p  0.05)
* Represents the mean ratio  SD by biodistribution; n  5.
† Represents the mean ratio  SD by autoradiography; n  3.icals and sacrif ced at the times shown in Table 3. The
nimal was then attached to the rotation device so that the
pper half of the animal was in the f eld-of-view and im-
ging begun. In the 6-[18F]FMT studies the rats were in-
ected with carbidopa (s.c. 5 mg/kg) 30 min prior to the
-[18F]FMT.
Target-to-non-target ratios were obtained from the Pi-
ET images in each of these cases by def ning three separate
egions-of-interest in the target region and three in the
eference region of each image. The regions were well
ithin the borders of the chosen tissue. Ratios were com-
uted from the average of the target values divided by the
verage of the non-target values. Each ratio represents the
atio from a single animal.
. Results
Since a reference tissue is not available for 2-[18F]FDG
nd gray to white ratios are diff cult to obtain, ratios of brain
issue to cerebellum for co-injected [14C]FDG and
-[18F]FDG in rats were obtained by autoradiography and
iodistribution studies (Table 4). The ratios were found to
e similar whether the images were obtained using autora-
iography with 50 Ci [14C]FDG or 4 mCi of 2-[18F]FDG
Table 4). Comparison of the ratios of the biodistribution
tudies using co-injected 10 Ci [14C]FDG or 100 Ci of
-[18F]FDG were also similar although the absolute ratios
ad a higher trend. Since the injected mass of FDG is small
ompared to the concentration found in plasma (5 mM) and
iven the capacity of the glucose transporters (GLUT) and
he velocity of hexokinase phosphorylation, this is not un-
xpected (see Sec. 4). The single distribution point is jus-
if ed based on previous studies showing that the radioac-
ivity in the brain is FDG 6-phosphate at this time point.
The mass effect of FCWAY and FMT was established
ver the range of 50 to 200 nmol per rat for FCWAY and 57
o 5645 nmol per rat for FMT (Tables 5 and 6). These data
how that, at 50 and 200 nmol/rat WAY100635, binding is
ecreased signif cantly in the tissues studied, whereas FMT
inding is not decreased over the experimental range.
Quantitation of 2-[18F]FDG, 6-[18F]FMT, and trans-
18F]FCWAY was carried out using autoradiography (Fig.
b–1d) and ex vivo counting of dissected rat brain and ratios
G (coinjected) determined by biodistribution and autoradiography at 30
Thalamus/CB Hippocampus/CB Brain stem/CB
1.26  0.04 1.03  0.03 0.98  0.03
1.28  0.02 1.05  0.04 0.99  0.04
1.48  0.15 1.14  0.10 1.29  0.20
1.47  0.11 1.19  0.03 1.24  0.21[14C]FD
CB
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5btained for these three radiopharmaceuticals (Table 7).
issues containing very low concentrations of receptor were
sed as a reference region.
FDG gave similar ratios using the two methods of anal-
sis (Table 7). When 5 mg/kg carbidopa was injected before
-[18F]FMT, the uptake in the striatum of the rat was clearly
isualized. The ratio of uptake in the caudate to cerebellum
as 1.7 using autoradiography. The ratio obtained by in-
ecting 1/60 of the dose used in the imaging experiment and
nalyzing tissue radioactivity by gamma counting was also
.7 at 45 min after injection (Table 8). The cerebellum is
sed as a reference tissue to normalize the study across
xperiments. The ratio in the target site of interest, the
audate, is the same in both experiments showing that at
hese mass differences, no mass effects were observed.
For trans-[18F]FCWAY, the hippocampus to cerebellum
atios obtained using biodistribution was 20, respectively
hile the hippocampus to cerebellum ratio was 19 by au-
oradiography (Table 7). Although the primary comparison
n this study was between the low dose biodistribution
tudies and the high dose autoradiography studies, PiPET
maging was also carried out. PiPET images of the distri-
utions of [18F]f uoride, 2-[18F]FDG, 6-[18F]FMT, and
rans-[18F]FCWAY in the rat head and brain are shown in
igs. 1a–1d. Since the binding of f uoride by bone is known
o be a non-saturable process, comparison with ex vivo
utoradiography was not carried out. The very high target-
o-non-target ratios, evident in the bone scan of the head, are
irtually identical to those observed in the CT scan of the
ame animal (Fig 1a). PiPET images of 2-[18F]FDG,
-[18F]FMT, and trans-[18F]FCWAY in the brain, shown in
igs. 1b–1d, gave similar ratios as those found by autora-
iography although these were obtained from the average of
hree determinations in a single animal (data not shown).
able 5
ass effect on trans-[18F]FCWAY distribution (DUR) in rat brain.
18F]FCWAY Cortex Hip
CA* 2.01  0.360 3.
50 nmol† 0.564  0.031 1.
200 nmol† 0.217  0.036 0.2
Values represent the mean DUR  SD, n  5. The raw data are taken f
or differences in animal weights.
* No-carrier-added.
† Mass of WAY 100635 coinjected.
able 6
ass effect on 6-[18F]FMT distribution (DUR) in rat brain.
18F]FMT Caudate Thala
7 nmol* 0.724  0.071 0.470
97 nmol* 0.667  0.119 0.476
645 nmol* 0.765  0.119 0.555
Values represent the mean DUR  SD, n  4–5.
18* Mass associated with [ F]FMT injected.iPET has been used in small animal studies and found to
e quantitative and of suff cient resolution for imaging den-
ritic cell migration [10], liver metabolism [11], and adrenal
umors [12].
. Discussion
Many studies on allometry suggest that the radiopharma-
eutical injection be scaled either by the body weight or by
he body surface area [13]. Many simple biological pro-
esses carried out in different species can be understood on
he basis of these relationships. Thus, if weights were used
s the allometric factor, the radioactivity injected into a rat
ould be scaled down by 0.25 kg/70 kg  1/280. With
his calculation, the dose injected into a rat to maintain the
ame percentage saturation would be 0.4 % of the human
ose. If the resolution of the PET scanner required for
nimal brains were no greater than that required for humans
5 mm), this amount would be appropriate. However, that
s clearly not the case.
It can be shown that although body weight scaling is
ppropriate if drug concentrations are to be the same in both
uman and animal, PET imaging in various species of
ifferent size requires a different relationship (Appendix I).
f we wish to visualize the rat brain with the same relative
cuity as we visualize the human brain, the volume of the
esolution voxel in the rat must be shrunk approximately in
roportion to the animal’s mass relative to the human mass
1/280). Moreover, if a rat and human PET study are to be
equivalent” from an imaging point of view, the same co-
ncidence rate must be observed from a rat resolution voxel
s from a human resolution voxel. It follows, therefore, that
he increase in dose with increasing resolution and the
pus Cerebellum Caudate
422 0.160  0.033 0.272  0.064
141 0.101  0.006 0.137  0.020
040 0.168  0.011 0.246  0.064
g et al. J Med Chem. 1999 (9) and transformed to DUR values to correct
Cerebellum Cortex
7 0.399  0.068 0.410  0.048
9 0.388  0.057 0.399  0.083
7 0.458  0.050 0.410  0.057pocam
05  0.
48  0.
67  0.
rom Lanmus
 0.04
 0.07
 0.054
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[ecrease in dose with decreasing body weight cancel one
nother and the amount of tracer we must administer to the
at is about the same as to the human. It also follows that if
rat receives this human tracer dose, the concentration of
rug in the animal will be higher in the ratio of human to rat
ody mass, potentially saturating vulnerable systems (the
bove argument ignores differences in attenuation, detec-
ion eff ciency but which are included in the Appendix).
imilar arguments can be made for brain imaging where the
atio in mass between humans and rat is approximately
,000.
In humans, nonsaturable sites (e.g. [18F]f uoride in bone)
nd intermediate saturable sites (e.g., 2-[18F]FDG to mea-
ig. 1. Comparison of images of the rat head obtained by PET (right pane
ifferent animals (left panels): (A) CT versus F-18 f uoride-transverse secti
ersus F-18 FMT-coronal section and (D) autoradiography versus F-18 FC
able 7
issue ratios obtained by phosphorimaging compared to dissection data.
adiopharmaceuticals Tissue ratio used
18F]FDG Caudate to cerebellum
-[18F]FMT with carbidopa Caudate to cerebellum
18F]FCWAY brain only Hippocampus to cerebel
Conditions given in Tables 1 and 2. Values in bold are signif cantly dif
* Mean ratio  SD; n  5.
† Mean ratio  SD; n  3.
‡ Mean ratio  SD; n  4.ure GLUT and hexokinase activity or 6-[18F]FMT) are not
ffected by low specif c activities or large injected masses.
o report of an effect of specif c activity using [18F]f uoride
s reported and the United States Pharmacopoeia proposes
he use of 2-[18F]f uoro-2-deoxyglucose at specif c activities
s low as 1 Ci/mmol for a 10 mCi dose of FDG. However,
n easily saturated processes such as the binding of radio-
racers to receptors, specif c activity plays an important part.
In general, to avoid physiologic effects in the tracer study
nd to avoid decreasing the target to non-target ratio signif-
cantly, the receptor saturation should be below 5%. This
an be seen from the equilibrium equation for binding
ttributed to Scatchard
pproximate spatial registration with images obtained by other methods in
autoradiography versus F-18 FDG-transverse section, (C) autoradiography
ransverse section. See Table 3 for details on the radiopharmaceutical dose.
Biodistribution Autoradiography
1.5 0.1* 1.7  0.1†
1.8 0.03* 1.7  0.1†
20.3  2.2 19.1  3.3‡
rom one (p  0.05)ls) in a
on, (B)
WAY-tlum
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776 E. M. Jagoda et al. / Nuclear Medicine and Biology 31 (2004) 771–7B/F  Bmax B/KD3 target to non-target ratio
here the bound concentration over the free concentration
atio (B/F) is related to the equilibrium dissociation constant
KD) and the total receptor concentration (Bmax).
Although the kinetic analysis would be affected by in-
reased mass, mostly by invalidating the assumption of f rst
rder kinetics used in most of the mathematical approaches,
he single scan technique employed here will be affected as
ell. The B/F, which will be the bound concentration over
he free concentration, is related to the maximum receptor
oncentration minus the bound concentration divided by the
D and therefore if the bound concentration is large com-
ared to the maximum receptor concentration, the observ-
ble B/F will be reduced. That equilibrium equation is the
asis of why we have compared B/F at different specif c
ctivities and total mass injected. Although a mathematical
pproach to second order kinetics is clearly possible, the
hysiologic effects, as demonstrated by Bolo, et al. [15] for
DG, are something to be avoided in tracer experiments.
ecent experiments with the muscarinic-2 receptor agonist,
18F]FP-TZTP, have also shown the physiologic effect of
ow specif c activity studies [14].
If we now return to the examples of three classes of PET
adiopharmaceuticals, we see that the uptake of [18F]f uo-
ide in bone will not be affected if we inject 1000 times
uman dose per kilogram in a rat. However, the use of the
uman dose of 2-[18F]FDG in rats may be more problematic
f FDG is used at the USP limit of 1 Ci/mmol. Since the
pecif c activity of FDG has been increased by 	1,000 with
he adoption of the Hamacher synthesis for FDG [7], the
hemical dose of FDG should not approach the saturation
evel of the enzyme involved. Bolo et al. [15] in studying
he metabolic trapping eff ciency of hexokinase in rabbit
rain found that 70 and 210 mg/kg altered the pharmaco-
inetics in the brain compared to no-carrier-added
18F]FDG. Bolo et al. [15] saw saturation at 0.38 mmol (70
g)/kg in rabbits. If saturation in rabbit brain is at 	0.38
mol/kg and the maximal human dose is 140 nmol/kg, then
here is a safety factor of 2,700 in the human brain. If
000 the dose is injected in a rat, there will be a small
afety factor using FDG prepared by electrophilic f uorina-
ion and a large safety factor for FDG prepared by the
ucleophilic f uorination proposed by Hamacher et al. [7].
here has also been a series of studies using [19F]FDG in
19
able 8
atio of tissue to cerebellum at 45 min after injection in rats at 0.050 mC
Dose
(Ci)
Cortex Cauda
18F]FMT 50 1.05  0.05* 1.69 
18F]FMT 3000 1.02  0.04† 1.84 
Values in bold are signif cantly different from one (p  0.05).
* Represents the mean ratio  SD; n  6.
† Represents the mean ratio  SD; n  3.ivo. [ F]FDG is the NMR active, stable isotope of f uo- hine. In order to obtain a measurable spectra with [19F]FDG
nd [19F]FDG 6-phosphate, the investigators used between
50 and 200 mg of [19F]FDG/kg. Physiologic effects were
bserved at 	200 mg/kg. Although the effect of mass par-
lleled that found in the [18F]FDG studies, the uptake of
18F]FDG and [19F]FDG was decreased by the added mass
nd the pharmacokinetics were altered [16].
A similar argument can be made for 6-[18F]FMT, al-
hough it is prepared primarily using electrophilic f uorina-
ion at lower specif c activities of 0.5–20 Ci/mmol. The
apacity of the various enzymes in the metabolic pathway of
MT in the rat are high, e.g., the AAAD activity in rat
lasma is 60 pmol/min/ml. Barrio et al. showed that even at
mg/kg carbidopa there was still peripheral AAAD metab-
lism [17]. They also showed that the rat striatum contained
bout half of the 6-[18F]f uorotyramine found in the rat
reated with carbidopa and very little 6-[18F]FMT. The
oncentration of AAAD in the rat brain is very high, 106.7
mol/min/g tissue [18]. In these situations where the radio-
igand is a substrate for a high capacity enzyme and the
lasma concentration of amino acids is 5 mM, decreasing
he uptake by saturating the target site is not likely. In fact,
imilar ratios of tissue to cerebellun (Table 8) was obtained
ith Ci and mCi injections in rat for 6-[18F]FMT. This is
rue for substrates for enzymes and transporters; inhibitors
f enzymes and transporters would have to be treated like
eceptor binding radiotracers because the enzyme does not
ct on the radiotracer in a catalytic manner.
In the case of receptor binding radiotracers, the use of a
,000radioactive dose per kg for brain scanning could
aturate the receptor above the 5% level. The calculations of
aturation level for receptor binding radiotracers is very
ependent on relatively small changes in specif c activity,
mount injected, and the percentage extracted by various
rain regions [19]. For example, for trans-[18F]FCWAY, the
verage 5-HT1A receptor concentration in the rat hippocam-
us is 80 nM [20]. With a 5 mCi injection of 1000 Ci/mmol
pecif c activity at the time of injection, the mass injected
ould be 5 nmol. Based on the value of 1.3 %ID/g observed
n the rat hippocampus, the concentration in a homogeneous
olution would be 65 nM. Taking the nonspecif c binding
alue of 0.06 %ID/g, the concentration of nonspecif c bind-
ng would be 3 nM. Comparing the bound concentration (65
M) with the hippocampal Bmax of 80 nM indicates that the
istribution) and 3 mCi (autoradiography) of 6-[18F]FMT.
Brain stem Thalamus Hippocampus
0.86  0.43 1.16  0.03 1.20  0.05
1.10  0.14 1.15  0.01 1.13  0.01i (biod
te
0.08
0.03ippocampal 5-HT1A receptor would be close to saturation.
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rmore rigorous calculation based on the equilibrium sat-
ration binding with ligand depletion and assuming equal
olumes of distribution indicates that the fraction of the
otal receptor occupied in the brain was 77% [21]. Motulsky
as published a formula where he includes nonspecif c bind-
ng [22]. This approach gave the same results in that the
otal receptor in the brain was near saturation. The 5-HT1A
eceptor concentrations in rats are similar to those found in
umans [23].
In the actual PiPET study performed with FCWAY (Ta-
le 3), the average specif c activity at time of injection was
283 Ci/mmol and the amount injected was 2 mCi. The
oncentration of bound material using the same %ID/g in
he hippocampus will be 0.6 nmol0.013/g or 8 nM. This
epresents 10% of the total hippocampal receptor concen-
ration whereas the previous calculation represented 77%
or a mass injection of 5 nmol. Calculations using the
pproach put forward by Selikson [21] and Motulsky [22]
lso gave an occupancy of 10%. These calculations were
ased on a Ki for FCWAY of 1 nM. In various in vitro tests,
e have obtained Ki values from 0.2 to 1 nM. Changing the
i from 1 to 0.2 nM did not change the occupancy signif-
cantly. In the f rst example, a 5 mCi injection of 1000
i/mmol (5 nmol) resulted in a calculated receptor satura-
ion of 77%. In the actual study, a 2 mCi dose of 3304
i/mmol; (0.6 nmol), the occupancy was reduced to 10%. It
s clear from these examples that relatively small changes in
ose resulted in major changes in occupancy.
There are two cautionary notes. The ratio of hippocam-
us to cerebellum in the biodistribution studies were com-
arable with that obtained with autoradiography (Table 7).
his may be the result of the ability to analyze a very
istinct region of the hippocampus with autoradiography
ersus the entire structure used for the biodistribution study.
e have compared the PSL units in the CA1 band with the
verage PSL in the entire hippocampus from the autora-
iography studies and found a ratio of 5 indicating that
egional differences were large.
Furthermore, the equations used here and those used by
ume et al. [19] and Meikle et al. [24] are equilibrium
quations and there is no indication that FCWAY is at
teady state in all tissues at 30 min after injection although
he net eff ux is similar in target tissue and metabolite
orrected plasma [9]. In conclusion, small differences can
hange the percentage saturation substantially and experi-
ents must be performed for each radiopharmaceutical at
he injected dose and specif c activity.
Hume et al. have carried out theoretical calculations
ased on the properties of three compounds with varying
ff nities for the limited number of target sites [19]. Hume
t al. [19] show that in the range of dose observed for WAY
00635, the occupancy would be very dependent on the
xact ED50 value. Meikle et al. [24] have made a similar
rgument, but concentrated on tomographic sensitivity us-
ng average values for brain uptake and specif c activities.
ecause small changes in aff nity and receptor concentra- iion have large effects on the occupancy, it is diff cult to
roject a rule of thumb for various compounds as discussed
bove.
. Conclusion
In present day practice we are far from obtaining the
heoretical specif c activity for 18F or 11C radiopharmaceu-
icals. However, for nonsaturable sites or high capacity sites
njecting a human dose into a rat should not affect the
harmacokinetics. For receptor binding radioligands, the
resent experimental specif c activities and the associated
ose could lead to partial saturation of the target site in rats
nd more certainly in mice. An increase in the effective
pecif c activity of the compound, an increase in the sensi-
ivity of the animal scanner relative to human PET scanners,
r both, will be required if new radiopharmaceuticals are to
e evaluated in animal models by external imaging without
hese limitations. Although probably not suff cient for mice,
CWAY PET scanning in rats is possible with presently
ttainable specif c activities and the sensitivity of contem-
orary small animal PET scanners.
ppendix
The relationship between human and rodent imaging can
e established by requiring that the same coincidence rate
e observed from a rodent imaging “voxel” as from the
uman imaging voxel, where “voxel” is def ned as the cube
f the (isotropic) spatial resolution of the imaging device. If
he subscript “r” refers to rodent and the subscript “h” refers
o human, then equal voxel activities will occur when:
SrCrVrr exp
uTrEr ShChVhh exp
uThEh
(1)
here Sspecif c activity (Ci/gm), Cdrug (radiophar-
aceutical) concentration (gm/gm), Vvoxel volume (cc),
tissue density (gm/cc), ulinear attenuation coeff cient
f tissue at 511 keV (1/cm), Th and Tr (in centimeters) are
he characteristic thicknesses of tissue across the body at the
ocation of the voxel of interest, and E is the fraction of
oincidence pairs detected by the animal and human PET
canners compared to the number emitted from the respec-
ive voxels.
Solving Eq. (1) for Cr gives
Cr 
Sh/Sr 
Vh/Vr 
Eh/Er exp
uTh TrCh
(2)
here we have assumed that the density of tissue in human
nd rat is the same. It is of interest to evaluate this expres-
ion for several relevant cases: when the same drug prepa-
ation is used in the rat as in the human, i.e. when SrSh and
n the case when CrCh.
7
a
u
m
s
3
t
I
p
h
e
t
u
t
h
t
t
c
t
p
f
i
r
s
b
e
s
P
a
f
t
h
c
s
a
t
w
r
t
e
a
2
c
a
s
h
s
d
v
c
t
r
l
c
b
w
t
s
s
m
R
[
[
[In either of these cases, the ratio of voxel volumes varies
pproximately as the ratio of body masses so that the vol-
me ratio can be replaced by the ratio of human to rat body
asses: 70,000 gm/250 gm280. If the transverse dimen-
ion of the human head is taken to be 18 cm and the rat head
cm, and the linear attenuation coeff cient to be 0.08/cm,
hen the exponential term in Eq. (2) takes on the value: 0.3.
n addition, current generation small animal PET scanner
ossess detection eff ciencies not terribly different from
uman PET scanners so the eff ciency ratio can also be set
qual to unity. In the f rst case, therefore, the expression for
he rat drug concentration becomes:
Cr 2800.3Ch
(3)
Cr 84Ch
That is, if the same drug, i.e., same specif c activity, is
sed to image both rat and human, the drug concentration in
he target tissue of the rat will be 84 times higher than in the
uman subject to obtain the same statistical image quality in
he same imaging time and same relative degree of resolu-
ion as in the human study.
In the second case, the condition necessary to make the
oncentrations equal in both rat and human is
SrEr/ShEh  84 (4)
This relation implies that in order to make the concen-
rations equal, the specif c activity-detection eff ciency
roduct for the rat study must be some 84 times greater than
or the human study. This elevated ratio can be achieved by
ncreasing the specif c activity of the compound used in the
at study by this factor, by increasing the sensitivity of the
mall animal PET scanner by this factor or by increasing
oth such that the product of specif c activity-detection
ff ciency is 84 for the rat study compared to the human
tudy. Given that the detection eff ciency of small animal
ET scanners cannot be improved realistically by more than
factor of about f ve relative to human PET scanners, it
ollows that even in the rat some increase (a factor of 17 in
his case) must be made in specif c activity if the rat and
uman studies are to be performed at identical drug con-
entrations.
If the condition expressed in Eq. (4) is not met and the
pecif c activity-detection eff ciency ratio is the same in rats
nd humans, the total amount of radioactivity administered
o the rat for imaging equivalency is given by the equation:
Ar 84Ah
Vr/Vh  84250/70,000Ah
(5)
Ar 0.3Ah
here A is the total injected activity. Therefore, human and
at equivalency can be obtained if the rat receives 30% of
he human dose. This dose, evidently, is not terribly differ-
nt from the human dose, a result contrary to intuition and
t odds with conventional allometry, which would predict a
80-fold reduction in injected activity for the rat. The cal-ulation here assumes that when a human is given a human-
ppropriate dose, the tracer does not saturate the human
ystem. The calculation also assumes that the duration of the
uman imaging study must also be matched by the animal
tudy. Since the total number of recorded coincidences
etermines the statistical precision of the measurement of
oxel activity, not just the coincidence rate, these conditions
an be relaxed depending on the temporal behavior of the
racer. For example, a tracer that goes to the brain and
emains f xed there can be imaged for extended periods at
east in principle. In such a case, the dose and tissue con-
entration could be lowered in the rat by giving less activity
ut imaging for a longer time. The equivalency condition
e have used here requires that tissue concentration, effec-
ive spatial resolution and total imaging time for the rat
tudy are identical to the human study and that the human
tudy exhibits satisfactory statistical precision of measure-
ent under these conditions.
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